The Relationships of Dehydroepiandrosterone Sulfate, Erectile Function and General Psychological Health

Kanglai Li, BD,1, Kanglai Li and Shangyan Liang, MD,2, Kanglai Li and Shangyan Liang contributed equally to this work as co-first authors.
Yuyan Shi, BD,2 Ying Zhou, MD,2 Liping Xie, BD,1 Jiali Feng, BD,2 Zhongcheng Chen, MD,3 Qingling Li, MD,2,# and Zhaoyu Gan, PhD4,#
#These authors contributed equally to the paper as co-corresponding authors.

ABSTRACT

Introduction: Dehydroepiandrosterone sulfate (DHEAS) has been reported to be associated with sexual function and general psychological health respectively, however, no one has ever examined their mutual relationships in a single study.

Aim: The aim of the present study was to find out whether DHEAS, general psychological health, and erectile function were all associated with each other.

Methods: A cross-sectional study was conducted on 34 patients with erectile dysfunction (ED) and 32 healthy controls (HC). The levels of serum DHEAS were assessed by chemiluminescence method. Erectile function and general psychological health were measured by International Index for Erectile Function-5 (IIEF-5) and General Health Questionnaire 20(GHQ-20) respectively.

Main Outcome measure: The primary outcome measure of this study was the mutual correlations of serum DHEAS levels, general psychological health and erectile function.

Results: Compared to HC, patients with ED had a significant lower serum levels of DHEAS (6.43 ± 2.70 μmol/L vs 9.48 ± 2.82 μmol/L, P < .001) and higher scores on GHQ-20 (35.06 ± 8.56 vs 24.97 ± 2.55, P < .001). Multivariate binary logistic regression showed that both serum levels of DHEAS (OR = 0.667, 95% CI = 0.512−0.869, P = .003) and psychological distress (scores of GHQ-20 > 28) (OR = 6.921, 95% CI = 1.821−26.305, P = .005) were significantly associated with ED. However, no significant association between psychological distress and serum levels of DHEAS was found (OR = 0.798, 95% CI = 0.623−1.021, P = .072) after controlling for ED. Partial correlation analysis revealed that both scores of GHQ-20 (r = −0.595, P < .001) and DHEAS (r = 0.450, P < .001) were significantly correlated with scores of IIEF-5, while no significant relationship was found between scores of GHQ-20 and DHEAS (r = 0.116, P = .363) after controlling for scores of IIEF-5 and age.

Conclusion: Both serum levels of DHEAS and general psychological health are significantly associated with erectile dysfunction in sexually active adult men but the relationship between general psychological health and erectile function seems to be independent of DHEAS. Li K, Liang S, Shi Y, et al. The Relationships of Dehydroepiandrosterone Sulfate, Erectile Function and General Psychological Health. Sex Med 2021;9:100386.

Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Key Words: Dehydroepiandrosterone Sulfate; Erectile Function; General Psychological Health; General Health Questionnaire 20

Received November 22, 2020. Accepted May 3, 2021.

1Department of Prevention and Healthcare Office, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;
2Department of VIP Medical Service Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;
3Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;
4Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
INTRODUCTION

Erectile dysfunction (ED) is a common disease in adult men with a high prevalence and incidence worldwide, accompanied by a young trend in recent years. According to the Massachusetts men’s aging study (MMAS), 52% of men aged 40–70 years have ED in varying degrees. A variety of endocrine hormones may be involved in the regulation of penile erection. However, among the 17 hormones investigated in MMAS subjects, dehydroepiandrosterone sulfate (DHEAS) is the only one significantly related to the occurrence of ED.

DHEAS is the most abundant steroid hormone in humans, mainly synthesized from dehydroepiandrosterone (DHEA) in the adrenal zona reticularis by hydroxysteroid sulftotransferase, both of which are regarded as representative of adrenal androgen. The serum DHEAS levels is about 250 times higher than serum DHEA levels, serving as the main form of DHEA/DHEAS. For adult men, the concentration of DHEA/DHEAS peaks between the ages of 20 and 30, and then decreases by 10% on average every 10 years. In addition, DHEAS is also abundant in brain where it can be synthesized de novo, contributing to regulate the activity of neurons.

DHEAS plays an important role in the regulation of sexual function. Previous studies showed that reduced serum levels of DHEAS increased the risk of ED in adult men, especially for elderly men. Serum levels of DHEAS were also found to be significantly lower in patients with ED than in age-matched healthy men. Moreover, DHEAS treatment was found to improve erectile function in patients with ED.

However, the mechanism about how DHEAS participates in the regulation of sexual function is not very clear. On one hand, DHEAS is the precursor of many other sex hormones, which are involved in the regulation of sex function. On the other hand, DHEAS can directly influence the function of vascular endothelial cells. Furthermore, DHEAS might impact on the mental health, which is regarded as an important factor associated with ED. As a proxy for overall health, perceived general health can buffer against the increased age-related risk of ED. Clinical studies have demonstrated that low DHEA levels are significantly associated with psychological disorders and depressive symptoms, which could be ameliorated by DHEA supplementation. However, the DHEA’s efficacy on mental health is yet to be confirmed. For example, a double blind crossover study found that healthy men with a physiological decline of DHEA production did not benefit from 4 months of DHEA supplementation.

To the best of our knowledge, no one has ever examined DHEAS, general psychological health and erectile function in a single study. What are the exact mutual relationships of them? Whether general psychological health is involved in the association between DHEAS and erectile function? To answer the questions, we are going to simultaneously assess serum levels of DHEAS, general psychological health and erectile function and then explore their mutual relationships among a sexually active male population.

MATERIALS AND METHODS

Participants

This is a cross-sectional study. All the cases in this study came from the inpatients that sought medical help because of erectile dysfunction in the VIP ward of the Third Affiliated Hospital of Sun Yat-sen University between August 1, 2017 and November 31, 2018. Patients were admitted to hospital to perform a thorough medical examination to exclude organic erectile dysfunction and receive a comprehensive treatment, which was hard to be completed in an outpatient visit. All the healthy controls (HC) came from the visitors who sought medical examination at the same period. All subjects were married or had a regular sexual partner, aged from 20 to 50 years, and were willing to submit written informed consent. For the case group, participants had to have a history of ED for more than 3 months and scored lower than 22 on IIEF-5 at the baseline. For the HC group, IIEF-5 score must be higher than 22 with the absence of history of ED. Participants who were currently suffering from any other DSM-IV-TR axis mental disorders or any active organic disease would be excluded. In addition, hormone, antidepressants, antipsychotics, antian drogens, antihistamines, and addictive drugs were not allowed to be taken in the last 6 months before entry into this study.

All procedures used in the present study were reviewed and approved by the Clinical Research Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University. (approval number: [2017]02-233-01).

Measurement

Laboratory testing. All the biochemical and hormonal measurements for an individual subject were performed by the same blood sample. Serum concentrations of total cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), fasting plasma glucose were measured via automated enzymatic assay by 7600-020 autoanmonic analyzer (Hitachi, Japan). Plasma hormones were assessed via chemiluminescence method as follows. The assay for the measurement of DHEAS, androstenedione, and adrenocorticotropic hormone (ACTH) were by IMI2000 (Siemens, Germany), for thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), Luteinizing hormone (LH), follicle stimulating hormone (FSH), total testosterone (TT), estradiol and prolactin were by I2000 (Abbott, USA), and for plasma cortisol were by Ceutaur XP (Siemens, Germany). The intra-assay and inter-assay coefficients of above variations were all lower than 10%, respectively. The reference levels of DHEAS for the male population in the assay were (2.17 ± 15.20) μmol/L.
**Erectile function assessment.** All subjects were assessed by the Chinese version of International Index for Erectile Function-5 (IIEF-5).\(^{19}\) IIEF-5 is a self-administered questionnaire, consisting of 5 items. Each item was rated on a scale of 1 (almost never or never) to 5 (almost always or always). A score of 0 indicated no attempt at sexual intercourse, and a score of lower than 22 were considered to have erectile dysfunction.\(^{19}\)

**Psychological health assessment.** Psychological health was measured with the Chinese version of General Health Questionnaire-20 items (GHQ-20).\(^{20}\) The questionnaire consisted of 20 items with responses over a 4-point scale (0–3), which ranged from “less than usual” to “much more than usual.”\(^{21}\) This scale included both positively phrased items implying psychological health and negatively phrased items implying psychological distress. A cut-off point of total score 28 was utilized as psychological distress.\(^{22}\)

**Statistical analysis**

Subjects were categorized into ED group and HC group according to the inclusion criteria. For normally distributed data, independent-sample \(t\)-test was used to test the difference between groups, while for non-normally distributed variables, comparison between groups were analyzed with Wilcoxon rank sum test. Differences in categorical parameters between groups were tested using Chi-square test. Multivariate binary logistic regression model was established to assess the relationships between ED, distress and DHEAS. Partial correlation analysis was used to test the relationships between IIEF-5, GHQ-20, and DHEAS. Odds ratios and 95% confidence intervals were used to quantify the strength of associations. The results were considered significant at \(P < .05\). All data were analyzed using commercial statistical package SPSS 24.0 (SPSS, Inc., Chicago, IL).

**RESULTS**

**Clinical and biochemical characteristics of the participants**

Totally, 34 ED patients and 32 healthy controls were involved in this study. Their clinical and biochemical characteristics were listed in Table 1. As the table demonstrated, the age of ED patients seemed to be smaller than that of HC, but only marginally reached significance (\(P = .093\)). No statistical differences was found in marital status, level of education, prevalence of smoking and drinking between ED group and HC group (all \(P > .05\)). All the subjects’ BMI, blood pressure, fasting blood glucose, plasma levels of lipid (TC, LDL, HDL, TG) and hormones including LH, FSH, TT, estradiol, prolactin, TSH, FT4, FT3, ACTH, and cortisol were in normal range, and did not statistically significantly differ between 2 groups.

**Comparisons of sexual hormones and level of erectile function, general psychological health between ED patients and healthy controls**

As shown in Table 2, serum levels of DHEAS and IIEF-5 were significantly lower in ED patients than in HC group, while the scores of GHQ-20 were significantly higher in ED patients than in HC (\(P < .001\)). In terms of prevalence of distress, the prevalence of distress was also significantly higher in ED patients than in HC (\(P < .001\)).

**Models of relationship between ED, distress and DHEAS**

Multivariate binary logistic regression equation was built respectively with ED (ED = 1, HC = 0) and psychological

| Table 1. Clinical and laboratory characteristics of all the subjects |
|------------------|------------------|------------------|
|                  | Erectile dysfunction \(n = 34\) | Healthy controls \(n = 32\) | \(P\) Value |
| Age (years)      | 36.47 ± 8.14     | 39.94 ± 8.39     | .093        |
| Married [n (%)]  | 30 (88.2)        | 29 (90.6)        | .535        |
| Education        |                  |                  |             |
| Primary school or lower | 5 (14.7) | 3 (9.4) | .775        |
| Middle or high school | 17 (50.0) | 21 (65.6) | .199        |
| College or higher | 12 (35.3)       | 8 (25.0)        | .363        |
| Alcohol drink [n (%)] | 4 (11.8) | 5 (15.6) | .460        |
| Smoking [n (%)]  | 7 (20.6)         | 7 (21.9)         | .568        |
| SBP (mmHg)       | 130.12 ± 6.92    | 127.81 ± 6.69    | .174        |
| DBP (mmHg)       | 76.32 ± 6.09     | 77.50 ± 6.19     | .439        |
| BMI (kg/m\(^2\)) | 24.64 ± 2.83     | 23.67 ± 2.55     | .151        |
| TC (mmol/L)      | 4.81 ± 0.82      | 4.87 ± 0.82      | .749        |
| LDL-C (mmol/L)   | 3.09 ± 0.88      | 3.11 ± 0.85      | .946        |
| HDL-C (mmol/L)   | 1.18 ± 0.32      | 1.22 ± 0.26      | .575        |
| TG (mmol/L)      | 1.21 (1.16,1.95) | 1.10 (1.02,1.44) | .156        |
| FBG (mmol/L)     | 5.12 ± 0.90      | 5.02 ± 0.51      | .555        |
| Cortisol (nmol/L) | 425.95 ± 98.59   | 399.21 ± 85.32   | .244        |
| ACTH (pmol/L)    | 4.28 ± 1.19      | 3.86 ± 1.39      | .187        |
| FT3 (pmol/L)     | 4.55 ± 0.93      | 4.66 ± 0.96      | .648        |
| FT4 (pmol/L)     | 16.75 ± 3.53     | 17.58 ± 3.04     | .315        |
| TSH (ulU/ml)     | 2.14 ± 0.95      | 2.24 ± 1.07      | .683        |

\(\text{ACTH} = \text{adrenocorticotrophic hormone; } \text{BMI} = \text{body mass index; } \text{DBP} = \text{diastolic blood pressure; } \text{FBG} = \text{fasting blood glucose; } \text{FT3} = \text{free triiodothyronine; } \text{FT4} = \text{free thyroxine; } \text{HDL-C} = \text{high-density lipoprotein cholesterol; } \text{LDL-C} = \text{low-density lipoprotein cholesterol; } \text{SBP} = \text{systolic blood pressure; } \text{TC} = \text{total cholesterol; } \text{TG} = \text{triglyceride; } \text{TSH} = \text{thyroid stimulating hormone.} \)
distress (distress = 1, non-distress = 0) as dependent variable, the other 2 variables as independent variables, and age as covariate. The results were displayed in Table 3. As seen in Table 3, model 1 showed that both serum levels of DHEAS (OR = 0.667, 95% CI = 0.512−0.869, P = .005) and distress (OR = 6.921, 95% CI = 1.821−26.305, P = .003) exerted impact on ED. According to model 2, serum levels of DHEAS imposed negative impact on distress but did not reach significance (OR = 0.798, 95% CI = 0.623−1.021, P = .072), while ED significantly influenced on distress (OR = 6.683, 95% CI = 1.788−24.982, P = .005).

distress (distress = 1, non-distress = 0) as dependent variable, the other 2 variables as independent variables, and age as covariate. The results were displayed in Table 3. As seen in Table 3, model 1 showed that both serum levels of DHEAS (OR = 0.667, 95% CI = 0.512−0.869, P = .005) and distress (OR = 6.921, 95% CI = 1.821−26.305, P = .003) exerted impact on ED. According to model 2, serum levels of DHEAS imposed negative impact on distress but did not reach significance (OR = 0.798, 95% CI = 0.623−1.021, P = .072), while ED significantly influenced on distress (OR = 6.683, 95% CI = 1.788−24.982, P = .005).

### Correlation between IIEF-5, GHQ-20, and DHEAS

Partial correlation analysis was conducted between IIEF-5, GHQ-20, and DHEAS with age as a covariate. The results were demonstrated in Table 4. According to Table 4, both scores of GHQ-20 (r = −0.595, P < .001) and DHEAS (r = 0.450, P < .001) were significantly correlated with scores of IIEF-5, while no significant relationship was found between scores of GHQ-20 and DHEAS (r = 0.116, P = .363) after controlling for scores of IIEF-5 and age.

### DISCUSSION

In line with most of previous studies, our study duplicates the finding that serum levels of DHEAS are significantly lower in patients with erectile dysfunction than age-matched healthy control. In addition, our study finds that erectile dysfunction is significantly associated with general psychological health, which is consistent with previous findings that perceived general health can decrease age-related risk of ED. DHEAS is considered as a weak androgen and pre-hormone that can convert to other androgen such as androstenedione and testosterone, which may be convenient for penile erectile. As inferred, DHEAS may exert its effect on erectile function through a G-protein dependent activation and induction of endothelial nitric oxide (NO) synthase independent of androgen receptors. The latter effect was

### Table 2. Comparisons of sex hormones and level of erectile function, general psychological health between ED and non-ED groups

|                      | Erectile dysfunction (n = 34) | Healthy controls (n = 32) | P Value |
|----------------------|-----------------------------|---------------------------|---------|
| DHEAS (µmol/L)       | 6.43 ± 2.70                 | 9.48 ± 2.82               | <.001   |
| Androstenedione (nmol/L) | 6.28 ± 3.08              | 6.83 ± 3.08               | .474    |
| Testosterone (nmol/L) | 13.18 ± 5.52                | 14.23 ± 5.70              | .450    |
| PRL (µIU/ml)         | 249.20 ± 98.36              | 242.03 ± 97.19            | .767    |
| LH (mIU/ml)          | 3.46 ± 1.32                 | 3.73 ± 1.41               | .426    |
| Estradiol (pmol/L)   | 138.95 ± 38.11              | 137.89 ± 33.13            | .904    |
| IIEF-5               | 11.29 ± 4.27                | 23.50 ± 1.08              | .001    |
| GHQ-20               | 35.06 ± 8.56                | 24.97 ± 2.55              | .001    |
| Psychological distress [n (%)] | 25 (73.5)          | 6 (18.8)                 | <.001   |

DHEAS = dehydroepiandrosterone sulfate; GHQ-20 = General Health Questionnaire 20; LH = luteinizing hormone; PRL = prolactin.

### Table 3. Models of relationship between ED, psychological distress and DHEAS by multivariate logistic regression analyses

|                      | Exp (B) | 95% CI         | P value* |
|----------------------|---------|----------------|----------|
| Model 1              |         |                |          |
| Psychological Distress| 6.921   | 1.821−26.305   | .005     |
| DHEAS                | 0.667   | 0.512−0.869    | .003     |
| Model 2              |         |                |          |
| DHEAS                | 0.798   | 0.623−1.021    | .072     |
| ED                   | 6.683   | 1.788−24.982   | .005     |

Note
*Adjusting for age.

1Multivarites binary logistic regression with ED as dependent variable.

1Multivarites binary logistic regression with distress as dependent variable.

DHEAS = dehydroepiandrosterone sulfate; ED = erectile dysfunction.

### Table 4. Correlations between IIEF-5, GHQ-20, and DHEAS

|                      | IIEF-5     | GHQ-20     | DHEAS     |
|----------------------|------------|------------|-----------|
| IIEF-5               | -          | −0.595 (<0.001)* | 0.450 (<0.001)* |
| GHQ-20               | −0.595 (<0.001)* | -          | −0.116 (0.363) |
| DHEAS                | 0.450 (<0.001) | −0.116 (0.363) | -         |

Note
*Controlling DHEAS and age.

1Controlling GHQ-20 and age.

1Controlling IIEF-5 and age.DHEAS = dehydroepiandrosterone sulfate; GHQ-20 = General Health Questionnaire 20; IIEF-5 = International Index for Erectile Function-5.
proved by the phenomenon in which DHEA increased NO production from intact endothelial cells in vitro.25

However, in contrast to our expectation, the association between erectile function and general psychological health is found to be independent of DHEAS. That is to say, the impact of general psychological health on erectile function seems not to be mediated by DHEAS. As far as we know, this has not been examined before. As a neurosteroid, DHEAS was found to have positive allosteric modulation on GABAA receptors at low, nanomolar concentrations.26 In animals, low dose of DHEAS was found to have anxiolytic effect.27 In human, serum level of DHEAS was proved to be a prediction of affective disorder.28 In addition, DHEAS level was also found to be negatively correlated with severity of depression14 in patient with major depression. However, the association between DHEAS and depressive symptoms could not be verified in the general population after controlling for potential confounding factors.29 Even in study with positive findings,30 the relationship between serum levels of DHEAS and general psychological health was only found in women, not in men. Moreover, no study has ever examined the relationships between sexual dysfunction, DHEAS and general psychological health simultaneously. Taking the Michael's study,14 as an example, it is hard to tell whether the association between DHEAS level and severity of depression would still exist after adjusting for erectile dysfunction, since sexual function was not assessed. The above-mentioned inconsistence between studies regarding the association between general psychological health and DHEAS reflects the effect of DHEAS on humans’ physical and mental well-being might be more complicated than we expected.

Caution should be exercised when interpreting this study’s results. First, the cross-sectional design of this study limits causal conclusions regarding the relationship between erectile dysfunction and general psychological health or DHEAS. Second, the sample size of this study is relatively small. However, the match in age, education, marital status, blood pressure, BMI, blood glucose, serum lipid, thyroid function and other neuroendocrinal hormones between case and control group helps improve the power of test. Third, only male subjects were recruited, so whether the conclusion about the relationship between general psychological health and DHEAS can be generalized to female is yet to be confirmed. Finally, patients with erectile dysfunction in this study were recruited only when they were admitted to our hospital for medical help, therefore, potential selection bias could not be excluded.

CONCLUSION

In conclusion, our study finds that both serum levels of DHEAS and general psychological health are significantly associated with erectile dysfunction in sexually active adult men but the relationship between general psychological health and erectile function seems to be independent of DHEAS.

Corresponding Author: Qingling Li, MD, Department of VIP Medical Service Center, The Third Affiliated Hospital of Sun Yat-sen University. NO.600, Tianhe Road, Tianhe District, Guangzhou, Guangdong 510630, China; E-mail: liqingl3@mail.sysu.edu.cn; Corresponding Author: Zhaoyu Gan, PhD, Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, NO.600, Tianhe Road, Tianhe District, Guangzhou, Guangdong 510630, China; E-mail: ganzhy@mail.sysu.edu.cn

Conflict of Interest: The authors report no conflicts of interest.

Funding: Funding for this study was provided by the Third Affiliated Hospital of Sun Yat-Sen University, Management Scientific Research Fund Projects (201805); the Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program and the Natural Science Foundation of Guangdong Province, China (2018A030313489).

STATEMENT OF AUTHORSHIP

Conceptualization and Data Curation, Zhaoyu Gan, Kanglai Li and Qingling Li; Funding Acquisition, Zhaoyu Gan and Kanglai Li; Methodology and Investigation, Yuyan Shi, Jiali Feng and Zhongcheng Chen; Project Administration and Formal Analysis, Kanglai Li, Shangyan Liang, Ying Zhou, Liping Xie; Resources, Kanglai Li and Zhongcheng Chen; Validation, Kanglai Li and Shangyan Liang; Writing — Original Draft, Kanglai Li and Shangyan Liang; Supervision and Writing — Review & Editing, Zhaoyu Gan, Qingling Li.

REFERENCES

1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Importance and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
2. Traish AM, Kang HP, Saad F, et al. Dehydroepiandrosterone (DHEA)—a precursor steroid or an active hormone in human physiology. J Sex Med 2011;8:2960–2982.
3. Labrie F, Bélanger A, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82:2403–2409.
4. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551–555.
5. Majewska MD, Demirgören S, Spivak CE, et al. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990;526:143–146.
6. Basar MM, Aydin G, Mert HC, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology 2005;66:597–601.
7. Morales A, Heaton JP, Carson CC. Andropause: a misnomer for a true clinical entity. J Urol 2000;163:705–712.
8. Reiter WJ, Pycha A, Schatzl G, et al. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology 2000;55:755–758.

9. Reiter WJ, Schatzl G, Märk I, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 2001;29:278–281.

10. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;81:3147–3151.

11. Gao J, Zhang X, Su P, et al. Relationship between sexual dysfunction and psychological burden in men with infertility: a large observational study in China. J Sex Med 2013;10:1935–1942.

12. Quek KF, Sallam AA, Ng CH, et al. Prevalence of sexual problems and its association with social, psychological and physical factors among men in a Malaysian population: a cross-sectional study. J Sex Med 2008;5:70–76.

13. Walther A, Mahler F, Debelak R, et al. Psychobiological protective factors modifying the association between age and sexual health in men: findings from the men’s health 40+ study. Am J Mens Health 2017;11:737–747.

14. Michael A, Jenaway A, Paykel ES, et al. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry 2000;48:989–995.

15. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154–162.

16. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133–141.

17. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001;86:4686–4692.

18. Huang YF, Li HJ. Practical Andrology (in Chinese), 1. Beijing: Science Press; 2009. p. 713.

19. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319–326.

20. Chan DW. The Chinese General Health Questionnaire in a psychiatric setting: the development of the Chinese scaled version. Soc Psychiatry Psychiatr Epidemiol 1993;28:124–129.

21. Bratas O, Grønning K, Forbord T. Psychometric properties of the Hospital Anxiety and Depression Scale and The General Health Questionnaire-20 in COPD inpatients. Scand J Caring Sci 2014;28:413–420.

22. Malt UF. The validity of the General Health Questionnaire in a sample of accidentally injured adults. Acta Psychiatr Scand Suppl 1989;355:103–112.

23. Samaras N, Samaras D, Frangos E, et al. A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? Rejuvenation Res 2013;16:285–294.

24. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(12,3). J Biol Chem 2002;277:21379–21388.

25. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004;69:279–289.

26. Majewska MD, Demirgören S, Spivak CE, et al. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990;526:143–146.

27. Melchior CL, Ritzmann RF. Dehydroepiandrosterone is an anxiolytic in mice on the plus maze. Pharmacol Biochem Behav 1994;47:437–441.

28. Srámková M, Dusková M, Hill M, et al. The role of steroids in the prediction of affective disorders in adult men. Steroids 2017;121:47–53.

29. Kische H, Gross S, Wallachofski H, et al. Associations of androgens with depressive symptoms and cognitive status in the general population. PLoS One 2017;12:e0177272.

30. Berr C, Lafont S, Debuire B, et al. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci U S A 1996;93:13410–13415.